Anita Midha

Statistics

Publications

Citations

618

H-Index

Active since

2008

Affiliations

AstraZeneca (United Kingdom)(Current)

Ventana Research Corporation (United States)

Anita Midha is an author at AstraZeneca (United Kingdom) specializing in cancer immunotherapy, programmed death-ligand 1 biomarker, and immune checkpoint inhibitors.

Publications per year

2008–2017

Publications

Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non–Small Cell Lung Cancer

M. Ratcliffe, Alan Sharpe, Anita Midha et al. · Clinical Cancer Research · 2017 · 304 citations

Medicine, Oncology, Cancer Immunology +16

Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma

Marlon C. Rebelatto, Anita Midha, Amita Mistry et al. · Diagnostic Pathology · 2016 · 179 citations · Full text

Medicine, Oncology, Cancer Immunology +16

Indazole-6-phenylcyclopropylcarboxylic Acids as Selective GPR120 Agonists with in Vivo Efficacy

William McCoull, Andrew Bailey, Peter Barton et al. · Journal of Medicinal Chemistry · 2017 · 33 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +8

Development of a PD-L1 companion diagnostic assay for treatment with MEDI4736 in NSCLC and SCCHN patients.

Marlon C. Rebelatto, Amita Mistry, Costi Sabalos et al. · Journal of Clinical Oncology · 2015 · 29 citations

Medicine, Immunology, Oncology +17

PD-L1 expression in advanced NSCLC: Primary lesions versus metastatic sites and impact of sample age.

Anita Midha, Alan Sharpe, Marietta Scott et al. · Journal of Clinical Oncology · 2016 · 28 citations

Medicine, Oncology, Pathology +17

1–5 of 7